New insights into the role of mTOR signaling in the cardiovascular system

S Sciarretta, M Forte, G Frati, J Sadoshima - Circulation research, 2018 - Am Heart Assoc
The mTOR (mechanistic target of rapamycin) is a master regulator of several crucial cellular
processes, including protein synthesis, cellular growth, proliferation, autophagy, lysosomal …

The role of mitochondrial dynamics in cardiovascular diseases

M Forte, L Schirone, P Ameri, C Basso… - British journal of …, 2021 - Wiley Online Library
The process of mitochondrial dynamics is emerging as a core player in cardiovascular
homeostasis. This process refers to the co‐ordinated cycles of biogenesis, fusion, fission …

[图书][B] Snapshots of hemodynamics: an aid for clinical research and graduate education

N Westerhof, N Stergiopulos, MIM Noble, BE Westerhof - 2018 - books.google.com
This book is written in a quick reference style to help clinical and basic researchers, as well
as graduate students, in the understanding of hemodynamics. Recent dev-opments in …

Cooperative binding of ETS2 and NFAT links Erk1/2 and calcineurin signaling in the pathogenesis of cardiac hypertrophy

Y Luo, N Jiang, HI May, X Luo, A Ferdous… - Circulation, 2021 - Am Heart Assoc
Background: Cardiac hypertrophy is an independent risk factor for heart failure, a leading
cause of morbidity and mortality globally. The calcineurin/NFAT (nuclear factor of activated T …

Novel Pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function

W Xu, C Billon, H Li, A Wilderman, L Qi, A Graves… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-
related receptors ERRα and ERRγ are essential regulators of cardiac metabolism …

Modeling human cardiac hypertrophy in stem cell-derived cardiomyocytes

E Ovchinnikova, M Hoes, K Ustyantsev, N Bomer… - Stem cell reports, 2018 - cell.com
Cardiac hypertrophy accompanies many forms of cardiovascular diseases. The mechanisms
behind the development and regulation of cardiac hypertrophy in the human setting are …

[HTML][HTML] Human antigen R as a therapeutic target in pathological cardiac hypertrophy

LC Green, SR Anthony, S Slone, L Lanzillotta… - JCI insight, 2019 - ncbi.nlm.nih.gov
RNA binding proteins represent an emerging class of proteins with a role in cardiac
dysfunction. We show that activation of the RNA binding protein human antigen R (HuR) is …

Emerging therapeutic targets for cardiac hypertrophy

AJ Winkle, DM Nassal, R Shaheen… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Cardiac hypertrophy is associated with adverse outcomes across
cardiovascular disease states. Despite strides over the last three decades in identifying …

Signalosome-regulated serum response factor phosphorylation determining myocyte growth in width versus length as a therapeutic target for heart failure

J Li, Y Tan, CL Passariello, EC Martinez, MD Kritzer… - Circulation, 2020 - Am Heart Assoc
Background: Concentric and eccentric cardiac hypertrophy are associated with pressure
and volume overload, respectively, in cardiovascular disease both conferring an increased …

Left ventricular hypertrophy and clinical outcomes over 5 years after TAVR: an analysis of the PARTNER trials and registries

H Gonzales, PS Douglas, P Pibarot, RT Hahn… - Cardiovascular …, 2020 - jacc.org
Objectives This study sought to evaluate the association between severity of left ventricular
hypertrophy (LVH) before transcatheter aortic valve replacement (TAVR) and outcomes out …